Shi X B, Bodner S M, deVere White R W, Gumerlock P H
Department of Urology, University of California, School of Medicine, Sacramento 95817, USA.
Diagn Mol Pathol. 1996 Dec;5(4):271-8. doi: 10.1097/00019606-199612000-00008.
To correlate molecular changes with clinical information in prostate tissue, it is necessary to have accurate methods for screening for mutations in clinically available specimens. We have refined the polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis for detection of p53 mutations in routine pathology specimens. These improvements help overcome technical barriers that interfere with SSCP analysis of archival tissues when only small amounts of poorly preserved formalin-fixed DNA are available. Furthermore, prostate samples are heterogeneous in containing tumor, normal tissue, and hyperplastic tissue. To address the first issue, the method included an initial selection of PCR products using exonuclease I, followed by a second-step selection using nested PCR. This step ensures adequate amplification of the target sequence while minimizing artifactual products that could otherwise interfere with mutation analysis. For the second issue, in addition to morphologic selection of appropriate tissue areas, we improved the sensitivity of detection of mutations by using restriction enzyme digestion of products prior to SSCP analysis. Detection of mutations in heterogeneous tissue was evaluated by determining the minimal detectable mutant allele frequencies in exons 4, 5, 6, 7, 8-9, and 10 by using mixtures of known mutant and wild-type cell lines, which were found to be 17.6, 9.1, 12.5, 8.1 14.0, and 14.3%, respectively. To determine the utility of this method when used on heterogeneous clinical samples, we performed study of 19 archival prostate specimens (14 primary prostate cancers, three benign prostatic hyperplasia and two metastases) and detected abnormally migrating products in six of the prostate cancer specimens (four primaries and two metastases). In five of these samples, there was sufficient DNA to perform sequencing, which disclosed single-base change mutations in all five samples.
为了将前列腺组织中的分子变化与临床信息相关联,必须拥有准确的方法来筛查临床可用标本中的突变。我们改进了聚合酶链反应-单链构象多态性(PCR-SSCP)分析方法,用于检测常规病理标本中的p53突变。当仅有少量保存不佳的福尔马林固定DNA时,这些改进有助于克服干扰存档组织SSCP分析的技术障碍。此外,前列腺样本包含肿瘤、正常组织和增生组织,具有异质性。为了解决第一个问题,该方法包括使用核酸外切酶I对PCR产物进行初步筛选,然后使用巢式PCR进行第二步筛选。这一步确保了靶序列的充分扩增,同时将可能干扰突变分析的人为产物降至最低。对于第二个问题,除了对合适的组织区域进行形态学选择外,我们还通过在SSCP分析之前对产物进行限制性酶切消化,提高了突变检测的灵敏度。通过使用已知突变和野生型细胞系的混合物,测定外显子4、5、6、7、8-9和10中最小可检测突变等位基因频率,评估异质组织中突变的检测情况,发现其分别为17.6%、9.1%、12.5%、8.1%、14.0%和14.3%。为了确定该方法用于异质临床样本时的实用性,我们对19份存档前列腺标本(14例原发性前列腺癌、3例良性前列腺增生和2例转移瘤)进行了研究,在6例前列腺癌标本(4例原发性和2例转移瘤)中检测到异常迁移产物。在其中5个样本中,有足够的DNA进行测序,结果显示所有5个样本均存在单碱基变化突变。